TIMP1 and inflammatory bowel disease: Previous analysis of TIMP1 expression levels using immunohistochemistry has shown significantly elevated levels in gastroenteropancreatic (Voland et al., 2008), bronchopulmonary (Blicharz-Dorniak et al., 2012), and primary skin (Massi et al., 2003) neuroendocrine tumors as well as the glandular epithelium of IBD (Jakubowska et al., 2016).